FindTrial
Sign In

A Study of LY3200882 in Participants With Solid Tumors

A Phase 1 Study of LY3200882 in Patients With Solid Tumors

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02937272
Enrollment
223
Registered
2016-10-18
Start date
2016-11-21
Completion date
2027-08-01
Last updated
2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumor

Keywords

TGF Beta

Brief summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Interventions

DRUGLY3200882

Administered orally

DRUGLY3300054

Administered intravenously

DRUGGemcitabine

Administered intravenously

DRUGnab-Paclitaxel

Administered intravenously

DRUGCisplatin

Administered intravenously

RADIATIONIntensity Modulated Radiotherapy

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The participant must have histological or cytological evidence of cancer. * Have adequate organ function. * Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1. * Are able to swallow capsules and tablets.

Exclusion criteria

* Have moderate or severe cardiovascular disease. * Have a serious concomitant systemic disorder. * Have acute leukemia.

Design outcomes

Primary

MeasureTime frame
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)Cycle 1 (28 days)
Part B: Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)Baseline through Disease Progression or Death (estimated at up to 12 months)

Secondary

MeasureTime frame
Pharmacokinetics (PK): Area Under the Curve (AUC) (AUC[0-24]) at Steady State of LY3200882Cycle 1 Day 1 through Cycle 2 Day 14 (28 day cycles)
PK: AUC Zero to Infinity (AUC[0-∞]) at Steady State of LY3200882Cycle 1 Day 1 through Cycle 2 Day 14 (28 day cycles)
ORR: Percentage of Participants with CR or PRBaseline through Disease Progression or Death (estimated at up to 12 months)
Overall Survival (OS)Baseline to Date of Death from Any Cause (estimated at up to 12 months)
Duration of Response (DoR)Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (estimated at up to 12 months)
Progression-Free Survival (PFS)Baseline to Disease Progression or Death (estimated at up to 12 months)

Countries

Australia, Canada, France, Germany, Italy, Japan, Spain, United States

Contacts

STUDY_DIRECTORCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Eli Lilly and Company

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026